2.4.0.84050 - Disclosure - Collaboration and License Agreements (Details)truefalsefalse1false USDfalsefalse$D2013Q2http://www.sec.gov/CIK0001235010duration2013-04-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDfalsefalse$D2012Q2http://www.sec.gov/CIK0001235010duration2012-04-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDfalsefalse$D2013Q2YTDhttp://www.sec.gov/CIK0001235010duration2013-01-01T00:00:002013-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDfalsefalse$D2012Q2YTDhttp://www.sec.gov/CIK0001235010duration2012-01-01T00:00:002012-06-30T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false truefalseD2011Q4_M10_SandozCollaboration2003Memberhttp://www.sec.gov/CIK0001235010duration2011-10-01T00:00:002011-10-31T00:00:00falsefalse2003 Sandoz Collaborationus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2003Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.momentapharma.com/20130630Itemmnta06false truefalseD2011Q3_M07_SandozCollaboration2003Memberhttp://www.sec.gov/CIK0001235010duration2011-07-01T00:00:002011-07-31T00:00:00falsefalse2003 Sandoz Collaborationus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2003Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.momentapharma.com/20130630Itemmnta07false USDtruefalse$D2010Q3_M07_SandozCollaboration2003Memberhttp://www.sec.gov/CIK0001235010duration2010-07-01T00:00:002010-07-31T00:00:00falsefalse2003 Sandoz Collaborationus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2003Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.momentapharma.com/20130630Itemmnta0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false USDtruefalse$D2013Q2_SandozCollaboration2003Memberhttp://www.sec.gov/CIK0001235010duration2013-04-01T00:00:002013-06-30T00:00:00falsefalse2003 Sandoz Collaborationus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2003Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9false USDtruefalse$D2012Q2_SandozCollaboration2003Memberhttp://www.sec.gov/CIK0001235010duration2012-04-01T00:00:002012-06-30T00:00:00falsefalse2003 Sandoz Collaborationus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2003Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false USDtruefalse$D2013Q2YTD_SandozCollaboration2003Memberhttp://www.sec.gov/CIK0001235010duration2013-01-01T00:00:002013-06-30T00:00:00falsefalse2003 Sandoz Collaborationus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2003Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.momentapharma.com/20130630Itemmnta0PureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11false USDtruefalse$D2012Q2YTD_SandozCollaboration2003Memberhttp://www.sec.gov/CIK0001235010duration2012-01-01T00:00:002012-06-30T00:00:00falsefalse2003 Sandoz Collaborationus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2003Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12false USDtruefalse$D2011_SandozCollaboration2003Memberhttp://www.sec.gov/CIK0001235010duration2011-01-01T00:00:002011-12-31T00:00:00falsefalse2003 Sandoz Collaborationus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2003Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13false USDtruefalse$I2013Q2_SandozCollaboration2003Member_MaximumMemberhttp://www.sec.gov/CIK0001235010instant2013-06-30T00:00:000001-01-01T00:00:00falsefalse2003 Sandoz Collaborationus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2003Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14false USDtruefalse$D2013Q2_SandozCollaboration2006Memberhttp://www.sec.gov/CIK0001235010duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$15false USDtruefalse$D2012Q2_SandozCollaboration2006Memberhttp://www.sec.gov/CIK0001235010duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$16false USDtruefalse$D2013Q2YTD_SandozCollaboration2006Memberhttp://www.sec.gov/CIK0001235010duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.momentapharma.com/20130630Itemmnta0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17false USDtruefalse$D2012Q2YTD_SandozCollaboration2006Memberhttp://www.sec.gov/CIK0001235010duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$18false USDtruefalse$I2013Q2_SandozCollaboration2006Member_MaximumMemberhttp://www.sec.gov/CIK0001235010instant2013-06-30T00:00:000001-01-01T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$19false USDtruefalse$D2006Q3_M07_NovartisPharmaAGMember_SandozCollaboration2006Memberhttp://www.sec.gov/CIK0001235010duration2006-07-01T00:00:002006-07-31T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseNovartis Pharma AGdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldimnta_NovartisPharmaAGMemberdei_LegalEntityAxisexplicitMemberSharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDPerShareDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20false USDtruefalse$D2013Q2_NovartisPharmaAGMember_SandozCollaboration2006Memberhttp://www.sec.gov/CIK0001235010duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseNovartis Pharma AGdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldimnta_NovartisPharmaAGMemberdei_LegalEntityAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$21false USDtruefalse$D2012Q2_NovartisPharmaAGMember_SandozCollaboration2006Memberhttp://www.sec.gov/CIK0001235010duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseNovartis Pharma AGdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldimnta_NovartisPharmaAGMemberdei_LegalEntityAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$22false USDtruefalse$D2013Q2YTD_NovartisPharmaAGMember_SandozCollaboration2006Memberhttp://www.sec.gov/CIK0001235010duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseNovartis Pharma AGdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldimnta_NovartisPharmaAGMemberdei_LegalEntityAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$23false USDtruefalse$D2012Q2YTD_NovartisPharmaAGMember_SandozCollaboration2006Memberhttp://www.sec.gov/CIK0001235010duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseSecond Sandoz Collaboration Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_SandozCollaboration2006Memberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseNovartis Pharma AGdei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldimnta_NovartisPharmaAGMemberdei_LegalEntityAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$24false USDtruefalse$D2013Q2_MassachusettsInstituteOfTechnologyMemberhttp://www.sec.gov/CIK0001235010duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseMassachusetts Institute of Technologyus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_MassachusettsInstituteOfTechnologyMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$25false USDtruefalse$D2012Q2_MassachusettsInstituteOfTechnologyMemberhttp://www.sec.gov/CIK0001235010duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseMassachusetts Institute of Technologyus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_MassachusettsInstituteOfTechnologyMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$26false USDtruefalse$D2013Q2YTD_MassachusettsInstituteOfTechnologyMemberhttp://www.sec.gov/CIK0001235010duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseMassachusetts Institute of Technologyus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_MassachusettsInstituteOfTechnologyMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.momentapharma.com/20130630Itemmnta0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$27false USDtruefalse$D2012Q2YTD_MassachusettsInstituteOfTechnologyMemberhttp://www.sec.gov/CIK0001235010duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseMassachusetts Institute of Technologyus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_MassachusettsInstituteOfTechnologyMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$28false truefalseD2012Q3_M07_BaxterAgreementMemberhttp://www.sec.gov/CIK0001235010duration2012-07-01T00:00:002012-07-31T00:00:00falsefalseBaxter Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_BaxterAgreementMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.momentapharma.com/20130630Itemmnta029false USDtruefalse$D2013Q2_BaxterAgreementMemberhttp://www.sec.gov/CIK0001235010duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseBaxter Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_BaxterAgreementMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$30false USDtruefalse$D2013Q2YTD_BaxterAgreementMemberhttp://www.sec.gov/CIK0001235010duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseBaxter Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_BaxterAgreementMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.momentapharma.com/20130630Itemmnta0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$31false USDtruefalse$D2013Q2_AccountingStandardsUpdate200913Member_BaxterAgreementMemberhttp://www.sec.gov/CIK0001235010duration2013-04-01T00:00:002013-06-30T00:00:00falsefalseBaxter Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_BaxterAgreementMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseAccounting Standards Update No. 2009-13us-gaap_AdjustmentsForNewAccountingPronouncementsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AccountingStandardsUpdate200913Memberus-gaap_AdjustmentsForNewAccountingPronouncementsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$32false USDtruefalse$D2012Q2_AccountingStandardsUpdate200913Member_BaxterAgreementMemberhttp://www.sec.gov/CIK0001235010duration2012-04-01T00:00:002012-06-30T00:00:00falsefalseBaxter Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_BaxterAgreementMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseAccounting Standards Update No. 2009-13us-gaap_AdjustmentsForNewAccountingPronouncementsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AccountingStandardsUpdate200913Memberus-gaap_AdjustmentsForNewAccountingPronouncementsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$33false USDtruefalse$D2013Q2YTD_AccountingStandardsUpdate200913Member_BaxterAgreementMemberhttp://www.sec.gov/CIK0001235010duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseBaxter Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_BaxterAgreementMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseAccounting Standards Update No. 2009-13us-gaap_AdjustmentsForNewAccountingPronouncementsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AccountingStandardsUpdate200913Memberus-gaap_AdjustmentsForNewAccountingPronouncementsAxisexplicitMemberItemStandardhttp://www.momentapharma.com/20130630Itemmnta0USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$34false USDtruefalse$D2012Q2YTD_AccountingStandardsUpdate200913Member_BaxterAgreementMemberhttp://www.sec.gov/CIK0001235010duration2012-01-01T00:00:002012-06-30T00:00:00falsefalseBaxter Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_BaxterAgreementMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseAccounting Standards Update No. 2009-13us-gaap_AdjustmentsForNewAccountingPronouncementsAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_AccountingStandardsUpdate200913Memberus-gaap_AdjustmentsForNewAccountingPronouncementsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$35false truefalseD2013Q2YTD_BaxterAgreementMember_MaximumMemberhttp://www.sec.gov/CIK0001235010duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseBaxter Agreementus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldimnta_BaxterAgreementMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli01true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0Collaborations and License Agreements2false 4mnta_CollaborativeArrangementSignificantDeliverablesIdentifiedNumbermnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse22falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16truefalsefalse22falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of significant deliverables identified in arrangement.No definition available.false256Number of significant deliverables identified in arrangement3false 4mnta_CollaborativeArrangementNumberOfThirdPartyCompetitorsMarketingInterchangeableGenericVersionmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse00falsefalsefalse6truefalsefalse00falsefalsefalse7truefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents information pertaining to the number of third-party competitors marketing an interchangeable generic version of Lovenox, or Lovenox-Equivalent Product.No definition available.false256Number of third-party competitors4false 4mnta_CollaborativeArrangementPercentageOfProfitSharingmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10truetruefalse0.450.45falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalse17falsetruefalse00falsefalsefalse18falsetruefalse00falsefalsefalse19falsetruefalse00falsefalsefalse20falsetruefalse00falsefalsefalse21falsetruefalse00falsefalsefalse22truetruefalse0.500.50falsefalsefalse23falsetruefalse00falsefalsefalse24falsetruefalse00falsefalsefalse25falsetruefalse00falsefalsefalse26falsetruefalse00falsefalsefalse27falsetruefalse00falsefalsefalse28falsetruefalse00falsefalsefalse29falsetruefalse00falsefalsefalse30falsetruefalse00falsefalsefalse31falsetruefalse00falsefalsefalse32falsetruefalse00falsefalsefalse33falsetruefalse00falsefalsefalse34falsetruefalse00falsefalsefalse35falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the percentage of net profit shared on sales of the product if no third-party competitors are marketing an interchangeable generic version of Product and Equivalent Product.No definition available.false0Percentage of contractual profits earned under collaborative arrangement5false 4mnta_CollaborativeArrangementRevenueRecognizedFromProfitShareAndRoyaltymnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse16000001600000USD$falsetruefalse9truefalsefalse1940000019400000USD$falsetruefalse10truefalsefalse70000007000000USD$falsetruefalse11truefalsefalse4140000041400000USD$falsetruefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe profit-share and royalty product revenue earned from the collaborative agreement, net of development and legal expenses.No definition available.false2Profit-share product revenue earned from the collaborative agreement, net of development and legal expenses6false 4mnta_CollaborativeArrangementPercentageOfRoyaltyUpToPreDefinedSalesThresholdmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10truetruefalse0.100.10falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalse17falsetruefalse00falsefalsefalse18falsetruefalse00falsefalsefalse19falsetruefalse00falsefalsefalse20falsetruefalse00falsefalsefalse21falsetruefalse00falsefalsefalse22falsetruefalse00falsefalsefalse23falsetruefalse00falsefalsefalse24falsetruefalse00falsefalsefalse25falsetruefalse00falsefalsefalse26falsetruefalse00falsefalsefalse27falsetruefalse00falsefalsefalse28falsetruefalse00falsefalsefalse29falsetruefalse00falsefalsefalse30falsetruefalse00falsefalsefalse31falsetruefalse00falsefalsefalse32falsetruefalse00falsefalsefalse33falsetruefalse00falsefalsefalse34falsetruefalse00falsefalsefalse35falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the percentage of royalty to be paid by Sandoz for net sales up to pre-defined sales threshold.No definition available.false0Percentage of royalty for net sales up to pre-defined sales threshold7false 4mnta_CollaborativeArrangementPercentageOfRoyaltyAbovePreDefinedSalesThresholdmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10truetruefalse0.120.12falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalse17falsetruefalse00falsefalsefalse18falsetruefalse00falsefalsefalse19falsetruefalse00falsefalsefalse20falsetruefalse00falsefalsefalse21falsetruefalse00falsefalsefalse22falsetruefalse00falsefalsefalse23falsetruefalse00falsefalsefalse24falsetruefalse00falsefalsefalse25falsetruefalse00falsefalsefalse26falsetruefalse00falsefalsefalse27falsetruefalse00falsefalsefalse28falsetruefalse00falsefalsefalse29falsetruefalse00falsefalsefalse30falsetruefalse00falsefalsefalse31falsetruefalse00falsefalsefalse32falsetruefalse00falsefalsefalse33falsetruefalse00falsefalsefalse34falsetruefalse00falsefalsefalse35falsetruefalse00falsefalsefalsenum:percentItemTypepureRepresents the percentage of royalty to be paid by Sandoz for net sales above pre-defined sales threshold.No definition available.false0Percentage of royalty for net sales above pre-defined sales threshold8false 4mnta_CollaborativeArrangementMilestonePaymentsPossiblemnta_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13truefalsefalse5500000055000000falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18truefalsefalse163000000163000000falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of milestone payments which the entity may receive for the entire length of the applicable agreement.No definition available.false2Milestone payments possible per agreement9false 4mnta_PeriodSinceDateOfProductApprovalDuringWhichNoCompetitorMarketedSimilarProductmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse001 yearfalsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period of time since the date of the FDA's approval during which no competitor marketed a similar product.No definition available.false0Period since date of product approval during which no competitor marketed similar product10false 4mnta_CollaborativeArrangementReductionInProductRevenueDueToSharedDevelopmentAndOtherExpensesmnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse38000003800000falsefalsefalse9truefalsefalse39000003900000falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryReduction in product revenue, related to shared development and other expenses.No definition available.false2Reduction in product revenue due to netting of shared development and other expenses11false 4mnta_CollaborativeArrangementResearchAndDevelopmentRevenueRecognizedmnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse800000800000falsefalsefalse9truefalsefalse12000001200000falsefalsefalse10truefalsefalse18000001800000falsefalsefalse11truefalsefalse21000002100000falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14truefalsefalse300000300000falsefalsefalse15truefalsefalse200000200000falsefalsefalse16truefalsefalse500000500000falsefalsefalse17truefalsefalse400000400000falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the research and development revenue from FTE services and external development costs upon completion of the performance requirements (i.e., as the services are performed and the reimbursable costs are incurred).No definition available.false2Research and development revenue recognized from FTE services and external development costs12false 4us-gaap_InventoryRawMaterialsNetOfReservesus-gaap_truedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCarrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 5.BB) -URI http://asc.fasb.org/extlink&oid=6386940&loc=d3e100047-122729 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 6 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 5 -Section BB Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)(4)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 false2Manufacturing raw material purchases13false 4mnta_CollaborativeArrangementSalesBasedAndCommercialMilestonePaymentsPossiblemnta_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18truefalsefalse153000000153000000falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of sales-based and commercial milestone payments which the entity may receive for the entire length of the applicable agreement.No definition available.false2Sales-based and commercial milestone payments possible per agreement14false 4mnta_StockPurchaseAgreementSharesSoldNumbermnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19truefalsefalse47086794708679falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:sharesItemTypesharesRepresents the number of shares sold pursuant to the terms of the Stock Purchase Agreement.No definition available.false1Number of shares sold15false 4mnta_StockPurchaseAgreementSharesSoldPricePerSharemnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19truefalsefalse15.9315.93USD$falsetruefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalRepresents the Per share price of number of shares sold pursuant to the terms of the Stock Purchase Agreement.No definition available.false3Per share price of shares sold16false 4mnta_CommonStockClosingPricemnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19truefalsefalse13.0513.05USD$falsetruefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsenum:perShareItemTypedecimalRepresents the closing price of the company's common stock on the NASDAQ Global Market.No definition available.false3Closing price of the company's common stock on the NASDAQ Global Market (in dollars per share)17false 4mnta_StockPurchaseAgreementSharesSoldAggregatePurchasePricemnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19truefalsefalse7500000075000000falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the aggregate purchase price of number of shares sold pursuant to the terms of the Stock Purchase Agreement.No definition available.false2Aggregate purchase price of shares sold18false 4mnta_StockPurchaseAgreementSharesSoldPremiummnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19truefalsefalse1360000013600000falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the premium paid on number of shares sold pursuant to the terms of the Stock Purchase Agreement.No definition available.false2Premium paid19false 4mnta_CollaborativeArrangementResearchAndDevelopmentRevenueRecognizedRelatedToPaidPremiummnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20truefalsefalse300000300000falsefalsefalse21truefalsefalse500000500000falsefalsefalse22truefalsefalse600000600000falsefalsefalse23truefalsefalse11000001100000falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the research and development revenue related to paid premium recognized during the period.No definition available.false2Research and development revenue related to paid premium recognized20false 4mnta_CollaborativeArrangementRegulatoryMilestonePaymentsPossiblemnta_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18truefalsefalse1000000010000000falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of regulatory milestone payments which the entity may receive for the entire length of the applicable agreement.No definition available.false2Regulatory milestone payments possible per agreement21false 4mnta_CollaborativeArrangementNumberOfFollowOnBiologicProjectsForDevelopmentAndCommercializationmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28truefalsefalse11falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse22falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of follow-on biologic products for development and commercialization under collaborative arrangement.No definition available.false256Number of follow-on biologic products for development and commercialization22false 4mnta_CollaborativeArrangementPeriodOfRightToSelectAdditionalFollowOnBiologicProductmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse003 yearsfalsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period of right to select additional follow-on biologic products with respect to development and commercialization of follow-on biologic products.No definition available.false0Period of right to select additional follow-on biologic products23false 4mnta_CollaborativeArrangementAdditionalNumberOfFollowOnBiologicProjectsForDevelopmentAndCommercializationmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse33falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of additional follow-on biologic products to be included in the collaborative arrangement.No definition available.false256Number of additional follow-on biologic products to be included in the collaboration24false 4mnta_CollaborativeArrangementCompanyOptionPercentageOfCostAndProfitSharingmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6falsetruefalse00falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalse11falsetruefalse00falsefalsefalse12falsetruefalse00falsefalsefalse13falsetruefalse00falsefalsefalse14falsetruefalse00falsefalsefalse15falsetruefalse00falsefalsefalse16falsetruefalse00falsefalsefalse17falsetruefalse00falsefalsefalse18falsetruefalse00falsefalsefalse19falsetruefalse00falsefalsefalse20falsetruefalse00falsefalsefalse21falsetruefalse00falsefalsefalse22falsetruefalse00falsefalsefalse23falsetruefalse00falsefalsefalse24falsetruefalse00falsefalsefalse25falsetruefalse00falsefalsefalse26falsetruefalse00falsefalsefalse27falsetruefalse00falsefalsefalse28falsetruefalse00falsefalsefalse29falsetruefalse00falsefalsefalse30falsetruefalse00falsefalsefalse31falsetruefalse00falsefalsefalse32falsetruefalse00falsefalsefalse33falsetruefalse00falsefalsefalse34falsetruefalse00falsefalsefalse35truetruefalse0.300.30falsefalsefalsenum:percentItemTypepureRepresents the percentage share of Company's option to participate, at its discretion, in a cost and profit share arrangement for the four additional products.No definition available.false0Percentage share of Company's option to participate, at its discretion, in a cost and profit share arrangement for the four additional products25false 4mnta_CollaborativeArrangementTotalArrangementConsiderationAgreedToBePaidmnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse6100000061000000falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the total arrangement consideration agreed to be paid by Baxter to the entity under collaborative arrangement.No definition available.false2Total arrangement consideration26false 4mnta_CollaborativeArrangementTotalArrangementConsiderationPortionAllocatedToFirstInitialProductLicensemnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse1030000010300000falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the total arrangement consideration allocated to the first initial product license together with the related research and development services.No definition available.false2Portion of arrangement consideration allocated to the first initial product license27false 4mnta_CollaborativeArrangementTotalArrangementConsiderationPortionAllocatedToEachAdditionalProductLicensemnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse1030000010300000falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the total arrangement consideration allocated to each of the four additional product licenses together with the related research and development services.No definition available.false2Portion of arrangement consideration allocated to each of the four additional product licenses28false 4mnta_CollaborativeArrangementTotalArrangementConsiderationPortionAllocatedToSecondInitialProductLicensemnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse94000009400000falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the total arrangement consideration allocated to the second initial product license together with the related research and development services.No definition available.false2Portion of arrangement consideration allocated to the second initial product license29false 4mnta_CollaborativeArrangementMilestonePaymentAllocatedToJointSteeringCommitteemnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse114000114000falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the total arrangement consideration allocated to joint steering committee.No definition available.false2Portion of arrangement consideration allocated to the joint steering committee unit of accounting30false 4mnta_CollaborativeArrangementUpfrontPaymentAgreedToBePaidmnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse3300000033000000falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the upfront payment agreed to be paid by Baxter to the entity under collaborative arrangement.No definition available.false2Upfront payment paid by Baxter to the company31false 4mnta_CollaborativeArrangementOptionPaymentsForAdditionalProductCandidatesmnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse2800000028000000falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the option payments agreed to be paid (with respect to additional product candidates) by Baxter under collaborative arrangement.No definition available.false2Option payments agreed to be paid by Baxter with respect to additional product candidates32false 4mnta_CollaborativeArrangementOptionPaymentsForEachOfExtensionsOfPeriodmnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse50000005000000falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the option payments agreed to be paid for each of the extensions of the period by the entity under collaborative arrangement. (To be paid by Baxter)No definition available.false2Option payments agreed to be paid for each of the extensions of the period33false 4mnta_CollaborativeArrangementTechnicalAndMilestonesPaymentAgreedToBePaidmnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse8000000080000000falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the technical and development milestone payment agreed to be paid by Baxter under collaborative arrangement.No definition available.false2Technical and development milestone payment agreed to be paid by Baxter34false 4mnta_CollaborativeArrangementNumberOfProductCandidatesmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse66falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of product candidates under collaborative arrangement.No definition available.false256Number of product candidates35false 4mnta_CollaborativeArrangementAggregateRegulatoryMilestonesToBePaidmnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsetruenegatedLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse300000000300000000falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the aggregate regulatory milestones agreed to be paid by Baxter under collaborative arrangement.No definition available.false2Aggregate regulatory milestones to be paid by Baxter36false 4mnta_CollaborativeArrangementNumberOfFollowOnBiologicProjectsForDevelopmentLicenseAndProductLicensemnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28truefalsefalse11falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse22falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of follow-on biologic products for development fees and product fees under collaborative arrangement.No definition available.false256Number of follow-on biologic products for development and product licenses37false 4mnta_CollaborativeArrangementAdditionalNumberOfFollowOnBiologicProjectsForDevelopmentFeesAndLicenseFeesmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse33falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of additional follow-on biologic products for development fees and product fees under collaborative arrangement.No definition available.false256Number of additional follow-on biologic products for development and product licenses38false 4mnta_CollaborativeArrangementNumberOfFollowOnBiologicProjectsForResearchAndDevelopmentServicemnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse22falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of follow-on biologic products for research and development service under collaborative arrangement.No definition available.false256Number of follow-on biologic products for research and development services39false 4mnta_CollaborativeArrangementAdditionalNumberOfFollowOnBiologicProjectsForResearchAndDevelopmentServicemnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse44falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of additional follow-on biologic products for research and development service under collaborative arrangement.No definition available.false256Number of additional follow-on biologic products for research and development services40false 4mnta_CollaborativeArrangementPerformancePeriodOfCombinedUnitsOfAccountingmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse66falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the performance period for each of the combined units of accounting consisting of the products and related research and development services, begins upon delivery of the related development and product license and ends upon FDA approval of the related product.No definition available.false256Number of combined units of accounting for performance period41false 4mnta_CollaborativeArrangementNumberOfInitialProductForPerformancePeriodmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33truefalsefalse22falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of initial product under performance period.No definition available.false256Number of initial product estimate for performance period42false 4mnta_CollaborativeArrangementNumberOfVendorsSellingSimilarCompetingProductOnStandAloneBasismnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of vendors selling similar, competing products on a stand-alone basis.No definition available.false256Number of vendors selling similar, competing products on a stand-alone basis43false 4mnta_CollaborativeArrangementRemainingPaymentObligationmnta_falsecreditinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29truefalsefalse00falsefalsefalse30truefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents remaining payment obligation with respect to a product in the relevant territory, unless earlier terminated by either party pursuant to the terms of the Baxter Agreement.No definition available.false2Remaining payment obligation44false 4mnta_CollaborativeArrangementEstimatePerformancePeriodForFirstInitialProductmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse005 yearsfalsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the estimate performance period for the first initial product considering stage of development.No definition available.false0Estimate performance period for the first initial product45false 4mnta_CollaborativeArrangementEstimatePerformancePeriodForSecondInitialProductmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse007 yearsfalsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the estimate performance period for the second initial product considering stage of development.No definition available.false0Estimate performance period for the second initial product46false 4mnta_CollaborativeArrangementEstimatePerformancePeriodForJointSteeringCommitteemnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse009 yearsfalsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the estimate performance period for the joint steering committee.No definition available.false0Estimate performance period for the joint steering committee47false 4mnta_CollaborativeArrangementLicensePaymentReceivableUponAchievementOfPredefinedMinimumDevelopmentmnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse2600000026000000falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the total potential license fees and milestones the entity is eligible to receive upon the achievement of pre-defined minimum development, as defined in the agreement.No definition available.false2Total potential license fees and milestones receivable upon the achievement of pre-defined minimum development48false 4mnta_CollaborativeArrangementMilestonePaymentReceivedmnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse380000000380000000falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the potential milestone payment received.No definition available.false2Potential milestone payments, in aggregate49false 4mnta_CollaborativeArrangementTechnicalAndMilestonePaymentFirstAnticipatedmnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse70000007000000falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the first technical and development milestone payment anticipated from Baxter under collaborative arrangement. This payment is due to the entity upon achievement of technical criteria for one of the products under the collaboration.No definition available.false2First anticipated technical and development milestone payment50false 4mnta_CollaborativeArrangementPeriodOfRightOfFirstNegotiationForCollaboratingInDevelopmentOfCompetingProductmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse003 yearsfalsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period of right of first negotiation with respect to collaborating in development of a competing product.No definition available.false0Period of right of first negotiation with respect to collaborating in development of a competing product51false 4mnta_CollaborativeArrangementNumberOfLicenseRelatedToResearchAndDevelopmentServicesmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse66falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of license agreements related to research and development services.No definition available.false256Number of license agreements52false 4mnta_CollaborativeArrangementNumberOfAccountingUnitsForRevenueRecognitionmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse66falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of accounting units for revenue recognition.No definition available.false256Number of accounting units for revenue recognition53false 4mnta_CollaborativeArrangementNumberOfOtherTimeBasedMilestonesmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30truefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of other time-based milestones included in the Baxter Agreement.No definition available.false256Number of other time-based milestones54true 4mnta_LicenseMaintenanceAndRoyaltyFeesAbstractmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0License, maintenance and royalties recorded55false 5us-gaap_LicenseCostsus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24truefalsefalse2100021000falsefalsefalse25truefalsefalse3900039000falsefalsefalse26truefalsefalse4100041000falsefalsefalse27truefalsefalse7900079000falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryCosts incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(e)) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2License and maintenance fees56false 5us-gaap_RoyaltyExpenseus-gaap_truedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24truefalsefalse1200012000falsefalsefalse25truefalsefalse366000366000falsefalsefalse26truefalsefalse9900099000falsefalsefalse27truefalsefalse786000786000falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryAmount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688 false2Royalties57false 5mnta_LicenseAndMaintenanceAndRoyaltyFeesmnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalsetotalLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24truefalsefalse3300033000falsefalsefalse25truefalsefalse405000405000falsefalsefalse26truefalsefalse140000140000falsefalsefalse27truefalsefalse865000865000falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents total of costs incurred and are directly related to generating license revenue, maintenance and amount of fees related to royalty payments under a contractual arrangement.No definition available.true2Total58false 4mnta_CollaborativeArrangementAnnualLicensePaymentmnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26truefalsefalse100000100000falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the annual license payment under collaborative arrangement.No definition available.false2Annual license maintenance fee59false 4mnta_CollaborativeArrangementNumberOfPatentsIssuedmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26truefalsefalse3030falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerRepresents the number of patents issued during the period.No definition available.false256Number of patents issued in the United States60false 4mnta_CollaborativeArrangementTermOfPatentsIssuedmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse0020 yearsfalsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the term of patents issued from the filing dated of application.No definition available.false0Term of patents from the filing date of application61false 4mnta_CollaborativeArrangementPeriodOfNonPaymentmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse0060 daysfalsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period of nonpayment by the entity considered from the date of a written notice for immediately terminating the collaborative agreement.No definition available.false0Period of nonpayment considered for immediately terminating the agreement62false 4mnta_CollaborativeArrangementPeriodOfMaterialBreachmnta_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse0090 daysfalsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:durationItemTypenaRepresents the period of material breach by the entity considered from the date of a written notice for immediately terminating the collaborative agreement.No definition available.false0Period of material breach considered for immediately terminating the agreement63false 4mnta_CollaborativeArrangementRevenueRecognizedOnAchievementOfCommercialMileStonemnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12truefalsefalse1000000010000000falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of revenue recognized during the period upon the achievement of commercial milestone.No definition available.false2Revenue earned and recognized upon achievement of a commercial milestone64false 4mnta_CollaborativeArrangementResearchAndDevelopmentRevenueRecognizedOnAchievementOfRegulatoryMileStonemnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse50000005000000falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of research and development revenue earned and recognized upon the achievement of a regulatory milestone.No definition available.false2Revenue earned and recognized upon the achievement of a regulatory milestone65false 4mnta_CollaborativeArrangementResearchAndDevelopmentRevenueRecognizedOnAmortizationOfUpfrontPaymentmnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31truefalsefalse700000700000falsefalsefalse32truefalsefalse800000800000falsefalsefalse33truefalsefalse14000001400000falsefalsefalse34truefalsefalse14000001400000falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of research and development revenue earned and recognized in the period by the entity upon amortization of the upfront payment.No definition available.false2Revenue earned and recognized upon amortization of the upfront payment66false 4mnta_CollaborativeArrangementRevenueRecognizedOnActivitiesRelatedToBiosimilarsDevelopmentmnta_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15falsefalsefalse00falsefalsefalse16falsefalsefalse00falsefalsefalse17falsefalsefalse00falsefalsefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29truefalsefalse600000600000falsefalsefalse30truefalsefalse600000600000falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryThe amount of revenue recognized during the period upon activities related to biosimilars development.No definition available.false2Revenue recognized upon activities related to biosimilars development67false 4us-gaap_ResearchAndDevelopmentExpenseus-gaap_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:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 2 -Paragraph 12, 13 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 141 -Paragraph 51 -Subparagraph g -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Statement of Financial Accounting Standard (FAS) -Number 86 -Paragraph 11, 12 -LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy. false2Shared development costs68false 4mnta_CollaborativeArrangementReductionInResearchAndDevelopmentRevenueDueToSharedDevelopmentCostmnta_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalse11falsefalsefalse00falsefalsefalse12falsefalsefalse00falsefalsefalse13falsefalsefalse00falsefalsefalse14falsefalsefalse00falsefalsefalse15truefalsefalse300000300000USD$falsetruefalse16falsefalsefalse00falsefalsefalse17truefalsefalse300000300000USD$falsetruefalse18falsefalsefalse00falsefalsefalse19falsefalsefalse00falsefalsefalse20falsefalsefalse00falsefalsefalse21falsefalsefalse00falsefalsefalse22falsefalsefalse00falsefalsefalse23falsefalsefalse00falsefalsefalse24falsefalsefalse00falsefalsefalse25falsefalsefalse00falsefalsefalse26falsefalsefalse00falsefalsefalse27falsefalsefalse00falsefalsefalse28falsefalsefalse00falsefalsefalse29falsefalsefalse00falsefalsefalse30falsefalsefalse00falsefalsefalse31falsefalsefalse00falsefalsefalse32falsefalsefalse00falsefalsefalse33falsefalsefalse00falsefalsefalse34falsefalsefalse00falsefalsefalse35falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the reduction in research and development revenue, related to the shared development costs.No definition available.false2Reduction in research and development revenue due to netting of shared development costsfalseCollaboration and License Agreements (Details) (USD $)NoRoundingNoRoundingNoRoundingUnKnowntruefalsefalseSheethttp://www.momentapharma.com/role/DisclosureCollaborationAndLicenseAgreementsDetails3568